NASDAQ:PLRX Pliant Therapeutics (PLRX) Stock Price, News & Analysis $1.23 +0.03 (+2.50%) Closing price 04:00 PM EasternExtended Trading$1.24 +0.01 (+0.41%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Pliant Therapeutics Stock (NASDAQ:PLRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pliant Therapeutics alerts:Sign Up Key Stats Today's Range$1.19▼$1.2550-Day Range$1.15▼$1.4152-Week Range$1.09▼$1.95Volume269,722 shsAverage Volume675,259 shsMarket Capitalization$76.16 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingReduce Company Overview Pliant Therapeutics, Inc. (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems. The company’s lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both αvβ1 and αvβ6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). In preclinical studies, Pliant has also advanced research-stage integrin modulators aimed at addressing fibrosis in diabetic nephropathy and other indications with high unmet medical need. Founded in 2015, Pliant has built its research and development capabilities around translational biomarkers and validated preclinical models. The company’s clinical programs are conducted through multi‐center studies in North America, with plans to expand patient enrollment into additional geographies as part of global development efforts. Leadership at Pliant is led by President and Chief Executive Officer Vikram Shembekar, who brings extensive biopharmaceutical development experience. The management team combines expertise in clinical development, regulatory strategy and commercialization planning, positioning the company to advance its integrin-targeted pipeline toward potential regulatory approvals and eventual patient access.AI Generated. May Contain Errors. Read More Pliant Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScorePLRX MarketRank™: Pliant Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 446th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingReduce Consensus RatingPliant Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 2 sell ratings.Upside PotentialPliant Therapeutics has a consensus price target of $3.00, representing about 142.9% upside from its current price of $1.24.Amount of Analyst CoveragePliant Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Pliant Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Pliant Therapeutics are expected to decrease in the coming year, from ($1.37) to ($1.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pliant Therapeutics is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pliant Therapeutics is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPliant Therapeutics has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Pliant Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.92% of the float of Pliant Therapeutics has been sold short.Short Interest Ratio / Days to CoverPliant Therapeutics has a short interest ratio ("days to cover") of 5.33.Change versus previous monthShort interest in Pliant Therapeutics has recently decreased by 5.75%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPliant Therapeutics does not currently pay a dividend.Dividend GrowthPliant Therapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.46 News SentimentPliant Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Pliant Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pliant Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders8.00% of the stock of Pliant Therapeutics is held by insiders.Percentage Held by Institutions97.30% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pliant Therapeutics' insider trading history. Receive PLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PLRX Stock News HeadlinesWall Street Zen Upgrades Pliant Therapeutics (NASDAQ:PLRX) to "Hold"May 19 at 1:10 AM | americanbankingnews.comPliant Therapeutics Stock Short Interest Report | NASDAQ:PLRX | BenzingaMay 17, 2026 | benzinga.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.May 21 at 1:00 AM | Weiss Ratings (Ad)Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 11, 2026 | finance.yahoo.comPliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare ConferenceMay 6, 2026 | globenewswire.comPliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid TumorsApril 30, 2026 | markets.businessinsider.comPliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid TumorsApril 30, 2026 | globenewswire.comPliant Therapeutics Presents Promising Phase 1b Trial Data for PLN-101095 in Combination with Pembrolizumab for ICI-Refractory Advanced Tumors at AACR 2026April 18, 2026 | quiverquant.comQSee More Headlines PLRX Stock Analysis - Frequently Asked Questions How have PLRX shares performed this year? Pliant Therapeutics' stock was trading at $1.22 on January 1st, 2026. Since then, PLRX stock has increased by 1.2% and is now trading at $1.2350. How were Pliant Therapeutics' earnings last quarter? Pliant Therapeutics, Inc. (NASDAQ:PLRX) released its quarterly earnings results on Monday, May, 11th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.04. When did Pliant Therapeutics IPO? Pliant Therapeutics (PLRX) raised $135 million in an IPO on Wednesday, June 3rd 2020. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager. Who are Pliant Therapeutics' major shareholders? Top institutional investors of Pliant Therapeutics include ADAR1 Capital Management LLC (4.17%), Renaissance Technologies LLC (2.99%), Eversept Partners LP (1.44%) and Redmile Group LLC (1.25%). Insiders that own company stock include Bernard Coulie, Keith Lamont Cummings, Eric Lefebvre, Hans Hull, Mike Ouimette and Minnie Kuo. View institutional ownership trends. How do I buy shares of Pliant Therapeutics? Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pliant Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pliant Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD). Company Calendar Last Earnings5/11/2026Today5/21/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 PLRX's financial health is in the Yellow zone, according to TradeSmith. PLRX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PLRX CIK1746473 Webpliantrx.com Phone650-481-6770FaxN/AEmployees90Year Founded2016Price Target and Rating Average Price Target for Pliant Therapeutics$3.00 High Price Target$3.00 Low Price Target$3.00 Potential Upside/Downside+143.9%Consensus RatingReduce Rating Score (0-4)1.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$149.34 million Net MarginsN/A Pretax MarginN/A Return on Equity-58.11% Return on Assets-44.37% Debt Debt-to-Equity RatioN/A Current Ratio16.89 Quick Ratio16.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book0.46Miscellaneous Outstanding Shares61,920,000Free Float56,966,000Market Cap$76.16 million OptionableOptionable Beta1.20 Social Links 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NASDAQ:PLRX) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
